Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non‐small‐cell lung cancer (NSCLC) harbouring an activating EGFR mutation. 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cochrane database of systematic reviews 2022-03, Vol.2022 (3)
Hauptverfasser: Occhipinti, Mario, Ferrara, Roberto, Imbimbo, Martina, Simeon, Vittorio, Fiscon, Giulia, Marchal, Corynne, Skoetz, Nicole, Viscardi, Giuseppe
Format: Artikel
Sprache:eng
Schlagworte:
Medicine General & Introductory Medical Sciences
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non‐small‐cell lung cancer (NSCLC) harbouring an activating EGFR mutation. 
ISSN:1465-1858
1465-1858
1469-493X
DOI:10.1002/14651858.CD015140